![]() |
|
|
Vol. 291, Issue 3, 1196-1203, December 1999
Division of Clinical Pharmacology and Experimental Therapeutics,
| |
Abstract |
|---|
|
|
|---|
We previously reported that the metabolism of cotinine, the proximate metabolite of nicotine, is significantly slower in black than in white cigarette smokers. To understand why the metabolism of nicotine and cotinine might differ between blacks and whites, we studied the pattern of nicotine metabolism in blacks and whites. One hundred eight healthy smokers (51 blacks and 57 whites), of similar age, gender distribution, and smoking history, received an i.v. infusion of deuterium-labeled nicotine and cotinine. The clearance of cotinine, the fractional conversion of nicotine to cotinine, and the metabolic clearance of nicotine to cotinine were significantly lower in blacks than in whites. Blacks excreted significantly less nicotine as nicotine-N-glucuronide and less cotinine as cotinine-N-glucuronide than whites, but there was no difference in the excretion of 3'-hydroxycotinine-O-glucuronide. Nicotine and cotinine glucuronidation appeared to be polymorphic, with evidence of slow and fast N-glucuronide formers among blacks but was unimodal with fast conjugators only among whites. Other findings of note included the demonstration of a significant correlation between the distribution volumes of nicotine and cotinine with lean body mass: there was a smaller distribution volume and a shorter half-life for cotinine in women than in men and a smaller volume of distribution of cotinine in blacks than in whites. We conclude that the metabolism of cotinine is slower in blacks than in whites because of both slower oxidative metabolism of nicotine to cotinine (presumably via cytochrome P-450 2A6) and slower N-glucuronidation. Ethnic differences in the metabolism of other drugs undergoing N-glucuronidation should be studied.
| |
Introduction |
|---|
|
|
|---|
We
recently reported that the metabolism of cotinine, the proximate
metabolite of nicotine, is significantly slower in black than in white
cigarette smokers (Perez-Stable et al., 1998
). Nicotine clearance was
on average lower in black smokers as well, but the difference was not
statistically significant.
Nicotine is metabolized primarily by C-oxidation to cotinine but is
also metabolized by N-oxidation to nicotine
N'-oxide and by N-glucuronidation (Fig.
1) (Benowitz et al., 1994
). Cotinine is
hydroxylated to trans-3'-hydroxycotinine and is metabolized by N-oxidation to cotinine N-oxide. Cotinine is
also metabolized by N-glucuronidation, and
3'-hydroxycotinine is metabolized by O-glucuronidation.
|
To understand why the metabolism of nicotine and cotinine might differ in blacks and whites, we studied the pattern of nicotine metabolite excretion in blacks and whites who received i.v. infusions of deuterium-labeled nicotine and cotinine.
| |
Materials and Methods |
|---|
|
|
|---|
Subjects.
One hundred eight volunteer cigarette smokers were
recruited through advertisements in local newspapers and from local
community colleges. The subjects included those whose clearance data
have been previously reported (Perez-Stable et al., 1998
), plus an additional 29 subjects studied subsequently. The demographic and smoking characteristics of the subjects are given in Table
1. Of the group, 37% were women (average
age, 34 years). By self-reports, the subjects smoked an average of 19 cigarettes per day and had smoked for an average of 18 years.
Eligibility criteria included 1) being in good health on the basis of
history, physical examination, electrocardiogram, and blood
chemistries; liver and kidney function tests were normal in all
subjects; 2) age of 21 to 64 years; 3) women had to be nonpregnant
based on surgical sterilization or negative pregnancy test; and 4)
self-identified as non-Latino, white, or black. Subjects were excluded
if there was habitual use of any prescription medication, narcotic or
sedative drug addiction, or chronic alcoholism. At the time of
eligibility evaluation, blood was collected and analyzed for
concentration of cotinine, the proximate metabolite of nicotine, which
is often used as a marker of daily nicotine intake (Benowitz, 1996
).
|
Experimental Procedure.
Eligible subjects were asked to come
to the Clinical Study Center at San Francisco General Hospital between
7 and 8 AM. Subjects were asked to abstain from food and cigarette
smoking from 10 PM the previous night until arrival at the Clinical
Study Center. Venous catheters were placed in both forearms. Subjects
received a simultaneous infusion of deuterium-labeled
nicotine-d2 (3',3'-dideuteronicotine) and
cotinine-d4 (2,4,5,6-tetradeuterocotinine) for 30 min. The syntheses of these deuterium-labeled compounds have been described previously (Jacob et al., 1988
; Jacob and Benowitz, 1993
). Subjects received 1.5 or 2.0 µg/kg/min for 30 min of nicotine-d2
and cotinine-d4 (calculated as the free base). During all
infusions, subjects were monitored by continuous electrocardiogram and
frequent blood pressure measurement. Two hours after the end of the
infusion, subjects were given a light breakfast. Subjects were allowed
to smoke their cigarettes freely after 1 PM.
Body Fat Measurement.
Body fat was estimated using the
skinfold thickness technique (Gibson, 1990
). This method involves
measuring skinfold thickness at four sites: triceps, biceps,
subscapular, and suprailiac regions. Skinfold thickness measurements
were used to estimate body density, which is then used to calculate
percent body fat.
Analysis of Nicotine and Metabolites in Biological Fluids.
Nicotine and metabolite concentrations were determined by gas
chromatography-mass spectrometry. Nicotine,
nicotine-3'-3'-d2, cotinine,
cotinine-2,4,5,6-d4,
trans-3'-hydroxycotinine,
trans-3'-hydroxycotinine-4',4'-d2, and
trans-3'-hydroxycotinine-2,4,5,6-d4 were
determined according to published methods (Jacob et al., 1992
, 1991
).
-glucuronidase, as described previously (Benowitz et al., 1994
-glucuronidase (EC 3.2.1.31; Helix Pomita, Fluka Chemical AG,
Milwaukee, WI).
Pharmacokinetic Analysis.
Pharmacokinetic parameters were
estimated from blood concentration and urinary excretion data using
model-independent methods as described previously (Benowitz and Jacob,
1994
). Total clearance was computed as:
|
|
|
cot) was computed as
CLnic × f.
Urine metabolite data were analyzed based on the urine collection over
8 h after the beginning of the nicotine and cotinine infusion.
Urine metabolite concentrations were expressed as a fraction of the
total nicotine plus metabolites recovered. The conjugates of nicotine
and its metabolites were also analyzed as ratios compared with the
unconjugated parent compound and as a fraction of parent compound plus
the conjugate.
Data Analysis. Group differences were compared with the use of ANOVA (race × gender). Correlation between the volume of distribution and body weight was determined by linear regression.
The distribution of urine metabolite ratios is shown using frequency histograms and probit plots. In the probit plot, the correlation frequency is expressed as the probit, with each probit number representing the width of 1 S.D. in the distribution from the mean (probit value at the mean = 0; Jackson et al., 1989| |
Results |
|---|
|
|
|---|
Subjects. Blacks and whites on average were of similar age, body weight, and lean body mass (Table 1). Blacks were much more likely to smoke menthol cigarettes (76%) than were whites (9%), although the average FTC (machine-determined) yields of nicotine and tar were similar. Blacks on average smoked fewer cigarettes per day but had higher average plasma cotinine concentrations during ad libitum smoking (P = NS). Blacks had significantly higher plasma cotinine normalized for cigarette consumption (17.0 ng/ml/cigarette) than whites (12.6 ng/ml/cigarette).
Disposition Kinetics. Blacks on average metabolized nicotine more slowly than whites, and blacks on average had a smaller volume of distribution of nicotine compared with whites, but the differences were not significant (Table 2). Blacks did convert significantly less nicotine to cotinine (81%) than whites (86%), and the clearance of nicotine via the cotinine pathway was significantly lower in blacks (14.8 ml/min/kg) than in whites (17.7 ml/min/kg).
|
Urine Metabolite Excretion. Metabolite excretion over the 8 h during and after infusion of nicotine, expressed as percent of total nicotine plus metabolite recovery, is shown in Table 3. Blacks excreted a significantly lower percentage of nicotine and metabolites as nicotine N-glucuronide and as cotinine N-glucuronide than did whites. This difference was seen both with deuterium-labeled nicotine (from the infusion) and nonlabeled nicotine (residual from prior cigarette smoking). Blacks excreted a significantly greater percentage of unlabeled alkaloids as cotinine compared with whites. The excretion of 3'-hydroxycotinine or 3'-hydroxycotinine glucuronide was similar in blacks and whites.
|
Conjugation of Nicotine and Metabolites. The percentage of labeled nicotine excreted as the N-glucuronide was significantly lower in blacks (25%) than in whites (40%; P < .01; Table 4). Similarly, the percentage of labeled cotinine excreted as the N-glucuronide was lower in blacks (21%) than in whites (35%; P < .001). A similar observation was made for unlabeled metabolite excretion. No ethnic differences were seen in the conjugation of 3'-hydroxycotinine (Table 4).
|
|
|
|
|
|
| |
Discussion |
|---|
|
|
|---|
This study provides novel findings in several areas. First, we
expanded our recent observations on ethnic differences in nicotine and
cotinine metabolism, providing data on a larger group of subjects. As
previously reported (Perez-Stable et al., 1998
), blacks metabolize cotinine significantly more slowly than do whites. We now find in the
larger group that the percent conversion of nicotine to cotinine and
the metabolic clearance of nicotine via the cotinine pathway are
significantly greater in whites than in blacks. We have also observed
gender differences, independent of ethnicity, in the volume of
distribution of cotinine and half-life; both are significantly lower in
women. Further analyses show that the volume of distribution of
cotinine is primarily related to lean body mass.
Second, we report that the extent of N-glucuronidation of nicotine and cotinine is on average less in blacks than in whites, which accounts for some but not all of the observed ethnic difference in the rate of metabolism of nicotine and cotinine. Third, we provide the first data on N-glucuronidation of nicotine and cotinine, as well as O-glucuronidation of 3'-hydroxycotinine, in groups of people. We find evidence of a polymorphic distribution of N-glucuronidation, with the slow metabolizers almost exclusively blacks. The population distribution of O-glucuronidation appears to be unimodal, with no ethnic differences.
The main difference between the present study and our previously
published study is the detailed metabolic profile of nicotine in blacks
and whites. This provides insight into the mechanisms of differences in
nicotine and cotinine metabolism. As noted previously, blacks on
average metabolize nicotine more slowly than whites, although this
difference is not statistically significant. In the present study, we
did find differences in the pattern of nicotine metabolism. Nicotine
metabolism via the cotinine pathway, which is known to be mediated
primarily by cytochrome P-450 (CYP) 2A6 (Nakajima et al., 1996b
), is
significantly slower, as was metabolism via
N-glucuronidation, in blacks than in whites.
Blacks were found to metabolize cotinine substantially more slowly than
whites, as seen in measurements of both total and nonrenal clearance.
Cotinine is metabolized primarily by CYP2A6 (Nakajima et al., 1996a
) to
trans-3'-hydroxycotinine and by conjugation to
cotinine-N-glucuronide. The observed slow metabolism of
cotinine in blacks appears to be due to both reduced CYP2A6 activity
and slower N-glucuronidation of cotinine. Of note, although
nonrenal clearance is slower, renal clearance of cotinine is faster in blacks than in whites, for unclear reasons.
The finding that the distribution volume of cotinine is significantly smaller in blacks than in whites (the distribution volume of nicotine was smaller by a similar 12% but was not significant) is a novel finding for which we have no explanation. We did explore various possible physiological factors that might explain distribution volume. We found that the distribution volume of cotinine was most highly correlated with lean body mass and was smaller in women than men. However, lean body mass and gender distribution were similar in blacks and whites, so these cannot explain the ethnic difference.
We report the novel observations that the half-life of cotinine is significantly longer in blacks than in whites and shorter in women than in men. The explanations for half-life differences are not the same. The half-life of cotinine was significantly longer on average because of lower clearance of cotinine in blacks than in whites. The half-life of cotinine was significantly shorter on average because of the smaller distribution volume of cotinine in women than in men.
Relatively little research has been done on
N-glucuronidation of drugs in general. Glucuronide formation
is the most widespread among phase 2 reactions in drug metabolism, but
for the most part these involve formation of acyl, hydroxyl, or
phenolic glucuronides (Miners and Mackenzie, 1991
; Kroemer and
Klotz, 1992
). The formation of N-glucuronides is described
as a significant metabolic pathway in humans for relatively few drugs
(Hawes, 1998
). Nicotine and cotinine have been shown to form
N-glucuronides (Curvall et al., 1991
; Byrd et al., 1992
;
Caldwell et al., 1992
; Benowitz et al., 1994
), as shown in Fig. 1. We
have previously shown a high correlation in the extent of
N-glucuronide formation between nicotine and cotinine within
individuals (Benowitz et al., 1994
), suggesting that the same enzyme is
involved in each. In contrast, the extent of
O-glucuronidation of 3'-hydroxycotinine is not correlated
with the conjugation of nicotine and cotinine, indicating that another enzyme is involved. Glucuronidation is catalyzed by UDP
glucuronosyltransferase (UGT) enzymes (Miners and Mackenzie, 1991
;
Kroemer and Klotz, 1992
). In humans, only UGT1A3 and UGT1A4 isoenzymes
have been shown to catalyze quaternary ammonium glucuronide formation
(Green and Tephly, 1998
). To date, the particular UGT isoenzyme
involved in N-glucuronidation of nicotine and cotinine or
O-conjugation of 3'-hydroxycotinine has not been determined.
We provide evidence that N-glucuronidation of nicotine and
cotinine is polymorphic, with a small group of slow metabolizers, most
of whom are black. Although the distribution of glucuronide ratios
appeared to be unimodal in whites, there was one slow metabolizer outlier (Figs. 2 and 5) who could represent a low prevalence
slow-metabolizing polymorphism in the white population. Another recent
report on the glucuronidation of the nicotine-derived nitrosamine
4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol (NNAL) showed a lesser
average extent of glucuronidation in blacks and evidence that blacks
predominated among slow metabolizers (Richie et al., 1997
). It is not
known whether NNAL forms an N-glucuronide or an
O-glucuronide, or both. However, the similarity in our
findings and those with NNAL suggests that ethnic differences among
NNAL, nicotine, and cotinine glucuronide formation reflect ethnic
differences in the same UGT isoenzyme.
Ethnic differences in N-glucuronidation of nicotine and
cotinine could be a result of genetic or environmental influences. The
finding that O-glucuronidation of 3'-hydroxycotinine is
similar in blacks and whites provides evidence that substrate
availability is not a determinant of ethnic differences in
glucuronidation. A possible effect of menthol in influencing the extent
of N-glucuronidation must be considered because most blacks,
but very few whites, smoke mentholated cigarettes. However, Richie et
al. (1997)
found in rats that menthol feeding does not decrease NNAL
glucuronidation, which presumably involves the same enzyme as nicotine
and cotinine glucuronidation, as discussed previously. The lack of
apparent environmental explanation suggests a genetic basis for the
ethnic difference in N-glucuronidation, but specific genetic
analyses are necessary to confirm this proposition.
Our data enable us to examine the quantitative importance of
differences in N-glucuronidation as the explanation for
differences in the metabolism of cotinine in blacks versus whites. In
the present study, we found that the total clearance of cotinine was 35% greater and the nonrenal clearance of cotinine was 46% greater in
whites than in blacks. In a previous study, we found that on average
12.6% of cotinine was excreted as cotinine glucuronide (Benowitz et
al., 1994
). Thus, even if blacks had no N-glucuronidation of
cotinine, 20% of the difference in total cotinine clearance would
still be unaccounted for. We did not measure cotinine
N-oxide or norcotinine, but these are minor metabolites,
accounting for 5% or less of cotinine clearance in combination
(Benowitz et al., 1994
). Thus, it is most likely that blacks metabolize
cotinine more slowly primarily because of lower CYP2A6 activity.
Consistent with this hypothesis is the observation that the clearance
of nicotine via the cotinine pathway, which is also believed to be determined by CYP2A6, was 20% greater in whites than in blacks.
The implications of our study are as follows. Cotinine clearance is
slower in blacks than in whites and in part explains why plasma and
urinary cotinine levels per cigarette smoked were significantly higher
in blacks than in whites in our study, as well as in a number of other
studies (Wagenknecht et al., 1990
; Carabello et al., 1998
; Perez-Stable
et al., 1998
). We also recently showed that blacks take in more
nicotine per cigarette, presumably through more intensive inhalation,
than whites, which also contributes to higher cotinine levels per
cigarette (Perez-Stable et al., 1998
). Ethnic differences, as well as
gender differences, in the half-life of cotinine could affect temporal
considerations in monitoring cotinine levels in smokers after cessation.
Our study also has implications regarding ethnic differences in drug
metabolism in general. Other researchers have reported black/white
differences in the metabolism of some drugs, with most research done on
the drug-metabolizing enzyme CYP2D6. CYP2D6 activity is known to be
polymorphically distributed, and a lower prevalence of slow
metabolizers due to a lower prevalence of a particular CYP2D6 mutant
gene has been reported in blacks than in whites (Evans et al., 1993
).
Conceivably, the opposite could be true for isozymes involved in
N-glucuronidation, with a greater prevalence of a mutant UGT
isomer gene in blacks. As noted previously, blacks form less
NNAL-glucuronide than do whites (Richie et al., 1997
). Ethnic
differences have also been reported for hydroxyglucuronide formation of
codeine between Chinese and whites of Swedish background (Yue et
al., 1989
).
| |
Acknowledgments |
|---|
We thank Patricia Buley and Sandra Tinetti for assistance in conducting the study and Kaye Welch for editorial assistance.
| |
Footnotes |
|---|
Accepted for publication August 2, 1999.
Received for publication April 27, 1999.
1 This work was supported by State of California Tobacco-Related Disease Research Program Grant 1RT-0521, United States Public Health Service Grants DA02277 and DA01696 awarded by the National Institute on Drug Abuse, Grants CA39260 and CA32389 awarded by the National Cancer Institute, Grant HS07373 awarded by the Agency for Health Care Policy and Research, and Grant 1P30-AG15272 awarded by the National Institute on Aging, the National Institute of Nursing Research, and the Office of Research on Minority Health and carried out in part at the General Clinical Research Center at San Francisco General Hospital with support of the Division of Research Resources, National Institutes of Health (Grant RR00083). E.J.P.-S. was a Henry J. Kaiser Family Foundation Faculty Scholar in General Medicine during the completion of the study.
Send reprint requests to: Neal L. Benowitz, M.D., Chief, Division of Clinical Pharmacology and Experimental Therapeutics, University of California, San Francisco, Box 1220, San Francisco, CA 94143-1220. E-mail: nbeno{at}itsa.ucsf.edu
| |
Abbreviations |
|---|
CL, clearance; AUC, area under the plasma concentration-time curve; CYP, cytochrome P-450; f, fractional conversion of nicotine to cotinine.
| |
References |
|---|
|
|
|---|
This article has been cited by other articles:
![]() |
J. Nussbaum, Q. Xu, T. J. Payne, J. Z. Ma, W. Huang, J. Gelernter, and M. D. Li Significant association of the neurexin-1 gene (NRXN1) with nicotine dependence in European- and African-American smokers Hum. Mol. Genet., June 1, 2008; 17(11): 1569 - 1577. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. K. Ho and R. F. Tyndale Role of CYP2A6 Genetic Variation on Smoking Behaviors and Clinical Implications ASCO Educational Book, January 1, 2008; 2008(1): 74 - 78. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. H. Lubin, N. Caporaso, D. K. Hatsukami, A. M. Joseph, and S. S. Hecht The Association of a Tobacco-Specific Biomarker and Cigarette Consumption and Its Dependence on Host Characteristics Cancer Epidemiol. Biomarkers Prev., September 1, 2007; 16(9): 1852 - 1857. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Jones-Burton, G. Vessal, J. Brown, T. C. Dowling, and J. C. Fink Urinary cotinine as an objective measure of cigarette smoking in chronic kidney disease Nephrol. Dial. Transplant., July 1, 2007; 22(7): 1950 - 1954. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. E. Wilson, R. S. Kahn, J. Khoury, and B. P. Lanphear The Role of Air Nicotine in Explaining Racial Differences in Cotinine Among Tobacco-Exposed Children Chest, March 1, 2007; 131(3): 856 - 862. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. C. K. Siu and R. F. Tyndale Characterization and Comparison of Nicotine and Cotinine Metabolism in Vitro and in Vivo in DBA/2 and C57BL/6 Mice Mol. Pharmacol., March 1, 2007; 71(3): 826 - 834. [Abstract] [Full Text] [PDF] |
||||
![]() |
X.-Y. Lou, J. Z. Ma, D. Sun, T. J. Payne, and M. D. Li Fine mapping of a linkage region on chromosome 17p13 reveals that GABARAP and DLG4 are associated with vulnerability to nicotine dependence in European-Americans Hum. Mol. Genet., January 15, 2007; 16(2): 142 - 153. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. M. Rasmusson, M. R. Picciotto, and S. Krishnan-Sarin Smoking as a complex but critical covariate in neurobiological studies of posttraumatic stress disorders: a review J Psychopharmacol, September 1, 2006; 20(5): 693 - 707. [Abstract] [PDF] |
||||
![]() |
W. M. Chatila, E. A. Hoffman, J. Gaughan, G. B. Robinswood, G. J. Criner, and for the National Emphysema Treatment Trial Researc Advanced emphysema in african-american and white patients: do differences exist? Chest, July 1, 2006; 130(1): 108 - 118. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Z. Ma, J. Beuten, T. J. Payne, R. T. Dupont, R. C. Elston, and M. D. Li Haplotype analysis indicates an association between the DOPA decarboxylase (DDC) gene and nicotine dependence Hum. Mol. Genet., June 15, 2005; 14(12): 1691 - 1698. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. D. Li, J. Beuten, J. Z. Ma, T. J. Payne, X.-Y. Lou, V. Garcia, A. S. Duenes, K. M. Crews, and R. C. Elston Ethnic- and gender-specific association of the nicotinic acetylcholine receptor {alpha}4 subunit gene (CHRNA4) with nicotine dependence Hum. Mol. Genet., May 1, 2005; 14(9): 1211 - 1219. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Hukkanen, P. Jacob III, and N. L. Benowitz Metabolism and Disposition Kinetics of Nicotine Pharmacol. Rev., March 1, 2005; 57(1): 79 - 115. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. S. Tepper, T. Williams-Nkomo, T. Martinez, J. Kisling, C. Coates, and J. Daggy Parental Smoking and Airway Reactivity in Healthy Infants Am. J. Respir. Crit. Care Med., January 1, 2005; 171(1): 78 - 82. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. L. Benowitz, B. Herrera, and P. Jacob III Mentholated Cigarette Smoking Inhibits Nicotine Metabolism J. Pharmacol. Exp. Ther., September 1, 2004; 310(3): 1208 - 1215. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. C. Windham, C. Bottomley, C. Birner, and L. Fenster Age at Menarche in Relation to Maternal Use of Tobacco, Alcohol, Coffee, and Tea during Pregnancy Am. J. Epidemiol., May 1, 2004; 159(9): 862 - 871. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. E. Kuehl and S. E. Murphy N-GLUCURONIDATION OF NICOTINE AND COTININE BY HUMAN LIVER MICROSOMES AND HETEROLOGOUSLY EXPRESSED UDP-GLUCURONOSYLTRANSFERASES Drug Metab. Dispos., November 1, 2003; 31(11): 1361 - 1368. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. D. Bjornsson, J. A. Wagner, S. R. Donahue, D. Harper, A. Karim, M. S. Khouri, W. R. Murphy, K. Roman, D. Schneck, D. S. Sonnichsen, et al. A Review and Assessment of Potential Sources of Ethnic Differences in Drug Responsiveness J. Clin. Pharmacol., September 1, 2003; 43(9): 943 - 967. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. T. Moolchan, I. Berlin, M. L. Robinson, and J. L. Cadet Characteristics of African American Teenage Smokers Who Request Cessation Treatment: Implications for Addressing Health Disparities Arch Pediatr Adolesc Med, June 1, 2003; 157(6): 533 - 538. [Abstract] [Full Text] [PDF] |
||||
![]() |
F. Patterson, N. Benowitz, P. Shields, V. Kaufmann, C. Jepson, P. Wileyto, S. Kucharski, and C. Lerman Individual Differences in Nicotine Intake per Cigarette Cancer Epidemiol. Biomarkers Prev., May 1, 2003; 12(5): 468 - 471. [Abstract] [Full Text] [PDF] |
||||
![]() |
O. Ghosheh and E. M. Hawes Microsomal N-Glucuronidation of Nicotine and Cotinine: Human Hepatic Interindividual, Human Intertissue, and Interspecies Hepatic Variation Drug Metab. Dispos., December 1, 2002; 30(12): 1478 - 1483. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Nakajima, E. Tanaka, J.-T. Kwon, and T. Yokoi Characterization of Nicotine and Cotinine N-Glucuronidations in Human Liver Microsomes Drug Metab. Dispos., December 1, 2002; 30(12): 1484 - 1490. [Abstract] [Full Text] [PDF] |
||||
![]() |
W K Al-Delaimy Hair as a biomarker for exposure to tobacco smoke Tob. Control, September 1, 2002; 11(3): 176 - 182. [Abstract] [Full Text] [PDF] |
||||
![]() |
|